

RealRate

PHARMACEUTICAL 2022











PHARMACEUTICAL 2022



RealRate

Xenetic Biosciences Inc. Rank 85 of 466

The relative strengths and weaknesses of Xenetic Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenetic Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Xenetic Biosciences Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 9.6% points.

The company's Economic Capital Ratio, given in the ranking table, is 245%, being 167% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	18,723
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,421
Liabilities, Non-Current	0
Other Assets	1,092
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	102
Other Revenues	1,161
Property and Equipment	0
Research and Development	3,163
Selling, General and Administrative Expense	3,744

Output Variable	Value in 1000 USD
Assets	19,815
Liabilities	1,421
Expenses	6,907
Revenues	1,161
Stockholders Equity	18,394
Net Income	-5,645
Comprehensive Net Income	-5,645
Economic Capital Ratio	245%

